Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-
Clinical Trials
Related News

Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery

Phase 4
Completed
Conditions
Carotid Stenosis
Interventions
Drug: Clopidogrel
First Posted Date
2010-06-17
Last Posted Date
2010-06-22
Lead Sponsor
R&D Cardiologie
Registration Number
NCT01146301
Locations
🇳🇱

St-Antonius Ziekenhuis, Nieuwegein, Utrecht, Netherlands

Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI

First Posted Date
2010-06-03
Last Posted Date
2012-10-04
Lead Sponsor
Lene Holmvang
Target Recruit Count
106
Registration Number
NCT01135667
Locations
🇩🇰

Rigshospitalet, Department of Cardiology, 2013, Copenhagen O, Denmark

Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Clopidogrel
First Posted Date
2010-05-24
Last Posted Date
2010-08-30
Lead Sponsor
Sanofi
Target Recruit Count
32
Registration Number
NCT01129063
Locations
🇫🇷

Sanofi-Aventis Administrative Office, Paris, France

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: clopidogrel
Drug: Matching placebo
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129271
Locations
🇫🇷

Sanofi-Aventis Administrative Office, Paris, France

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Clopidogrel
Drug: Placebo
Drug: Pantoprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
66
Registration Number
NCT01129427
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Clopidogrel
Drug: Omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129414
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: clopidogrel
Drug: omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129388
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: clopidogrel
Drug: placebo
Drug: omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129375
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: CLOPIDOGREL
Drug: placebo
First Posted Date
2010-05-14
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
40
Registration Number
NCT01123824
Locations
🇩🇪

Sanofi-Aventis Administrative Office, Berlin, Germany

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Clopidogrel
First Posted Date
2010-05-07
Last Posted Date
2022-11-23
Lead Sponsor
Scripps Health
Target Recruit Count
41
Registration Number
NCT01118793
Locations
🇺🇸

Scripp Health, La Jolla, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy